The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Kidney Int
; 97(1): 202-212, 2020 01.
Article
in En
| MEDLINE
| ID: mdl-31791665
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vasodilation
/
Diabetes Mellitus, Type 2
/
Diabetic Nephropathies
/
Sodium-Glucose Transporter 2 Inhibitors
/
Kidney
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Kidney Int
Year:
2020
Type:
Article